maria luz calibo
Oct 15, 2011

Apotex Will Postpone Generic Sales of Roche’s Boniva During Patent Case - Bloomberg

Apotex Inc. agreed to delay selling a generic version of the osteoporosis drug Boniva until a judge rules on the validity of a Roche Holding AG (ROG) patent on the medicine that expires in March 2012. Apotex, based in Toronto, is seeking U.S. Food and Drug Administration approval to sell a copy of Boniva. In 2007, Roche sued in federal court in Newark, New Jersey, claiming its patent is valid and enforceable, and that Apotex infringed it.